Evotec SE (EVO) Debt Ratio (2009 - 2026)

Evotec SE (EVO) posted Debt Ratio of 0.24 for Q1 2026, down 99.91% sequentially from 261.81 in Q4 2025, and down 4.0% YoY from 0.25 in Q1 2025.

Evotec SE (EVO) Debt Ratio (2009 - 2026) Analysis & Trends

Evotec SE has reported Debt Ratio for 9 years, with the latest figure at 0.24 in Q1 2026.

Quarterly Debt Ratio fell 4.0% year-over-year to 0.24 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.24 (down 4.0% YoY) and the FY2025 annual result came in at 261.81, up 112790.49% from the prior year.
Debt Ratio declined to 0.24 in Q1 2026 per EVO's latest filing, from 261.81 in the prior quarter.
Over five years, Debt Ratio peaked at 261.81 in Q4 2025 and troughed at 0.0 in Q3 2024.
A 5-year average of 25.86 and a median of 0.25 in 2025 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2024 and 2025: Debt Ratio sank 98.04% in 2024, then surged 115783757.49% in 2025.
Over 5 years, Debt Ratio stood at 9.23 in 2022, then rose by 28.15% to 11.83 in 2023, then tumbled by 98.04% to 0.23 in 2024, then jumped by 112790.49% to 261.81 in 2025, then slumped by 99.91% to 0.24 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.24, 261.81, and 0.27 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	-0.13
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	0.42
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	0.60
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	0.32
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	-
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	0.38
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	-
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	0.29
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	0.12
10	Evotec SE	687.23 Mn	686.75 Mn	-	0.24

Download Data